Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Lixte Biotechnology Holdings (LIXT) Equity Average (2016)

Lixte Biotechnology Holdings' Equity Average history spans 6 years, with the latest figure at $988551.5 for Q3 2016.

  • For Q3 2016, Equity Average fell 7.25% year-over-year to $988551.5; the TTM value through Sep 2016 reached $988551.5, down 7.25%, while the annual FY2015 figure was $274299.5, N/A changed from the prior year.
  • Equity Average reached $988551.5 in Q3 2016 per LIXT's latest filing, down from $1.1 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.8 million in Q3 2012 to a low of -$93264.5 in Q1 2012.
  • Average Equity Average over 5 years is $876392.4, with a median of $903724.8 recorded in 2012.
  • Peak YoY movement for Equity Average: surged 1549.0% in 2013, then tumbled 94.82% in 2014.
  • A 5-year view of Equity Average shows it stood at $1.6 million in 2012, then crashed by 74.54% to $408292.0 in 2013, then surged by 92.13% to $784440.5 in 2014, then dropped by 28.79% to $558608.5 in 2015, then soared by 76.97% to $988551.5 in 2016.
  • Per Business Quant, the three most recent readings for LIXT's Equity Average are $988551.5 (Q3 2016), $1.1 million (Q2 2016), and $672210.5 (Q1 2016).